PERSPECTIVE article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1712238
Budesonide/formoterol for Pediatric Asthma: Bridging the Gap Between Evidence and Practice in Maintenance and Reliever Therapy
Provisionally accepted
- Yan'an People's Hospital, Yan’an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Budesonide/formoterol is established as a foundational therapy for moderate-to-severe pediatric asthma, with extensive evidence supporting its efficacy in both maintenance and Maintenance and Reliever Therapy regimens. Its dual pharmacologic profile provides distinct advantages in exacerbation reduction and symptom control. However, clinical implementation faces persistent challenges, including diagnostic uncertainty in young children, technical difficulties in device use, variable adherence, and perceptual barriers among clinicians and caregivers. Future advancement requires targeted research into phenotype-specific treatment responses, integration of digital health technologies for personalized management, and systematic reform in education and policy. A multidisciplinary effort is essential to achieve more precise, effective, and sustainable asthma control in the pediatric population.
Keywords: pediatric asthma, Budesonide, Formoterol, Asthma management, Treatment Adherence, personalized medicine
Received: 24 Sep 2025; Accepted: 15 Oct 2025.
Copyright: © 2025 Tian, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dong-mei Wang, dong-meiwang@outlook.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.